CCC Diagnostics, Inc Awarded Qualifying Therapeutic Discovery Project Grant
CCC Diagnostics Inc of Baltimore, MD. has been awarded a Qualifying Therapeutic Discovery Project grant. This grant was awarded to further development and commercialization of the DirectHitTM Test Panel for Breast Cancer.

BALTIMORE, MD, January 21, 2011 /24-7PressRelease/ -- CCC Diagnostics, Inc. has received a grant of $244,479.25 under the Qualifying Therapeutic Discovery Project created by Congress as a component of the Patient Protection and Affordable Care Act of 2010, signed by President Obama on March 23, 2010. This grant was awarded to further development and commercialization of the DirectHitTM Test Panel for Breast Cancer.

DirectHit is a vastly improved diagnostic test for breast cancer treatment that accurately predicts the tumor's response to four commonly prescribed classes of anti-cancer drugs. The DirectHit Test Panel is the only diagnostic test which can predict the responsiveness of breast cancer patients to two classes of chemotherapy drugs, taxanes and capecitabine. In addition, DirectHit is significantly more accurate than existing tests for estrogen receptor and the HER-2/neu.

John Hughes, CEO of CCC Diagnostics, commented " We are very pleased to receive this grant. The funding will allow us to expand the technology of the DirectHit and aid more patients and their physicians in making informed choices about their treatments".

Press Release Contact Information:

scott deamond
CCC Diagnostics Inc
Technical director
3918 Vero Rd. Suite B
Baltimore, MD
United States 21227
Voice: 410-633-4885
Website: Visit Our Website